Skip to main content
2023 ACVIM Forum Main banner
Final Program


2023 Event Program
Icon Legend
This session is not on your agenda.
This session is on your agenda. Click again to remove it.
Presentation Icons
ACVIM Resident Research Award Eligible
ACVIM Resident Research Award Eligible
Additional Fees May Be Required
Additional Fees May Be Required
By Invite Only
By Invite Only
Capturing for On Demand
Capturing for On Demand
Cardiology Research Abstract Award Eligible
Cardiology Research Abstract Award Eligible
ERC Approved Lecture for ACVIM Residency
ERC Approved Lecture for ACVIM Residency
ePoster
ePoster
Livestream
Livestream
One Health
One Health
Pre-Registration Required
Pre-Registration Required
RACE-Approved
RACE-Approved
Research Abstract
Research Abstract
Specialty Symposium
Specialty Symposium
State-of-the-Art (SOTA) Presentation
State-of-the-Art (SOTA) Presentation
Veterinary Technician
Veterinary Technician
Back

Amy K. LeBlanc, DVM, DACVIM (Oncology)

Senior Scientist and Director
NIH/NCI/CCR Comparative Oncology Program
Bethesda, Maryland, United States

Dr. Amy LeBlanc is a Senior Scientist and the Director of the Comparative Oncology Program. Dr. LeBlanc received her DVM from Michigan State University in 1999, followed by a rotating internship at Texas A&M University, and residency training in veterinary medical oncology at Louisiana State University. She subsequently joined the faculty of the University of Tennessee’s College of Veterinary Medicine, and was awarded tenure in 2010. Dr. LeBlanc held a joint appointment with the University of Tennessee’s Graduate School of Medicine and was head of the UT’s Molecular Imaging and Translational Research Program from 2010 – 2014. She then joined the NCI in 2014 as the head of the Comparative Oncology Program. In this position she conducts preclinical mouse and translational canine studies that are designed to inform the drug and imaging agent development path for human cancer patients, specifically those with osteosarcoma. She also advises leading pharmaceutical companies as well as NCI’s Division of Cancer Treatment and Diagnosis on the inclusion of pet dogs with cancer into the development path of novel approaches for a variety of malignancies, including immunotherapeutics, targeted small molecules, oncolytic viruses, and cancer imaging agents. She directly oversees the NCI Comparative Oncology Trials Consortium (COTC), which provides infrastructure necessary to connect participating veterinary academic institutions with stakeholders in drug development to execute fit-for-purpose comparative clinical trials in novel therapeutics and imaging agents.

Presentation(s):